Bard PowerPort Catheter Lawsuit 2026 — MDL 3081 First Trial Update

A cancer patient received a chemotherapy port. The catheter fractured. Fragments migrated toward his heart. This is the story at the center of the Bard PowerPort litigation.

MDL 3081 involves over 3,300 patients who allege that Becton Dickinson’s Bard PowerPort catheter — made from barium sulfate-compounded silicone — failed structurally, causing fractures, infections, and blood clots. The first bellwether trial began April 21, 2026. The judge already stripped the defendant’s most powerful defense. The outcome of the next several trials will determine whether this MDL settles globally or fragments.

The Bard PowerPort: Device Design and the Defect Theory

An implantable vascular access port is a closed, self-sealing chamber placed subcutaneously — typically below the clavicle — with a catheter running through the subclavian or jugular vein into the superior vena cava. Once implanted, clinicians access the port through the skin with a special needle, eliminating the need for repeated peripheral IV insertions.

Why barium sulfate matters: Barium sulfate is added to silicone catheter material to make it radiopaque — visible on X-ray, fluoroscopy, and CT. This is essential for confirming catheter placement and detecting migration. The problem alleged by plaintiffs: barium sulfate particles embedded in the silicone matrix act as stress concentration points, accelerating fatigue failure of the silicone. Over time, cyclical movement from breathing, arm motion, and cardiac pulsation causes micro-fractures to propagate from these stress points until the catheter breaks.

The affected products are the PowerPort, Eclipse Port, X-Port, and related models with this barium sulfate silicone catheter formulation.

Becton Dickinson’s defense position: BD argues the products met FDA standards, were manufactured correctly, and that catheter fracture is a known — not concealed — complication of all long-term implanted vascular access devices, not unique to their product. They contend infections and thrombosis arise from patient factors, not product defects.

MDL 3081 Structure and Case Volume

Item	Detail
MDL Number	3081
Full Title	In re Bard Implanted Port Catheter Products Liability Litigation
Established	August 8, 2023
Court	District of Arizona, Phoenix Division
Judge	David G. Campbell
Defendant	Bard Access Systems (Becton Dickinson, BDX)
Case Count	~3,384 (May 2026)
First Bellwether	April 21, 2026 (ongoing)

Judge Campbell is an experienced MDL judge who also presided over the Bard IVC Filter MDL — the identical defendant, similar product defect theory, same courtroom. His comfort level with Bard’s corporate structure and internal document landscape is higher than a judge encountering the defendant for the first time. That familiarity cuts both ways, but it means complex evidentiary questions will be handled efficiently.

The Critical Pre-Trial Ruling: No 510(k) Safety Argument

In product liability cases involving FDA-cleared medical devices, defendants routinely argue: “The FDA reviewed this device and cleared it for market — that means it’s safe.” Judge Campbell rejected this argument pre-trial, barring BD from making this inference to the jury.

Why this matters profoundly:

The FDA’s 510(k) premarket notification process does not require clinical trials. It asks whether a new device is substantially equivalent to a legally marketed predicate device. A device can receive 510(k) clearance without any independent assessment of whether it is safe or effective in clinical use.

By stripping BD of this defense, Judge Campbell has required the case to turn on actual evidence of what BD knew, when they knew it, and what the device’s failure rate actually is in the field — not on the halo of regulatory approval. This is an exceptionally plaintiff-favorable ruling.

Talcum Powder Ovarian Cancer Lawsuit — Comparing Medical Product Liability Structures

The Cook Bellwether Case: What’s at Stake

The first bellwether trial involves Robert Cook, a Minnesota colorectal cancer patient who was hospitalized for six days in 2022 after his Bard PowerPort catheter became infected. Key facts:

• Infection caused a two-week delay in chemotherapy treatment
• Port removal surgery required
• Cook and his family complied with all care instructions
• His wife testified about how carefully they followed every protocol

This case type — infection rather than fracture — was strategically selected as the first bellwether because it is intuitively compelling to a jury: a cancer patient doing everything right, yet harmed by a defective device during the most vulnerable period of their life.

The fracture cases are structurally more dramatic (metal fragments floating toward the heart), but infection cases are factually simpler to explain. Plaintiff attorneys typically lead with the cleaner causation narrative.

As of May 1, 2026, the trial was ongoing. Five additional bellwether cases span infection, thrombosis, and fracture categories — running through early 2027.

My assessment: If Cook wins, BD faces settlement pressure to avoid multiple consecutive plaintiff verdicts. If Cook loses, BD will likely defend through the remaining bellwethers before entertaining settlement. The IVC Filter precedent — same defendant, same judge, eventual confidential multi-hundred million dollar settlement — suggests BD’s long-term posture is settlement, not indefinite trial. The question is how many bellwethers need to run first, and at what damages level.

Comparing PowerPort to Bard IVC Filter Litigation

Item	Bard IVC Filter MDL	Bard PowerPort MDL 3081
Defendant	Bard (Becton Dickinson)	Bard (Becton Dickinson)
Judge	David G. Campbell	David G. Campbell
Device	Inferior vena cava filter	Implantable port catheter
Core injury	Filter fracture, migration, perforation	Catheter fracture, migration, infection
FDA recall	Yes	Yes (Class 2, 2020)
Outcome	Multi-tranche confidential settlements	Ongoing — bellwethers in progress

The structural similarity is striking. Same judge, same defendant, same fracture-and-migration defect theory. BD eventually settled IVC Filter cases after years of litigation. The PowerPort MDL is likely to follow a similar arc, with settlement timing tied to bellwether outcomes.

Cancer Patients and the Compounding Harm

PowerPort injuries are uniquely damaging because they occur during cancer treatment — a period of maximum vulnerability.

Catheter infection during chemotherapy: Immunocompromised cancer patients are at elevated infection risk. A catheter-related bloodstream infection (CRBSI) during chemotherapy can require:

• Immediate hospitalization and IV antibiotics
• Cessation of cancer treatment for weeks
• Surgical port removal and re-implantation (often after infection resolves)
• Potential ICU admission for sepsis

Each delay in chemotherapy is a delay in treating an active cancer. The damages argument in these cases extends beyond the infection itself to the potential effect of the treatment interruption on cancer outcomes.

Catheter fracture with migration: A fractured catheter fragment must be retrieved percutaneously (via interventional radiology) or surgically. Fragments in the pulmonary artery can cause pulmonary hypertension or perforation. This is emergency-level intervention, often requiring general anesthesia in a patient already physically depleted by chemotherapy.

What Records to Gather

If you or a family member had a Bard PowerPort and experienced complications:

Device records:

• Operative report from the port implantation surgery (identifies manufacturer and model by name, serial/lot number)
• Implant card (given to patients at implant — identifies device)
• Contact your hospital’s device records department if you don’t have these

Complication records:

• For infection: hospitalization records, blood culture reports, antibiotic treatment records, port removal operative report
• For fracture/migration: fluoroscopy or CT reports showing fragment location, interventional radiology or surgical records for fragment retrieval
• For thrombosis: duplex ultrasound, CT pulmonary angiogram, anticoagulation treatment records

Impact documentation:

• Records of any chemotherapy treatment delays or cancellations
• Oncology notes addressing treatment plan changes
• Functional impairment documentation

Statute of Limitations and Discovery Rule

The SOL for product liability runs from the injury or discovery of the injury. For PowerPort cases:

• Infection: typically from hospitalization date
• Fracture discovery: from imaging date that identified the fragment
• Unknown migration: from date the complication was reasonably discoverable (e.g., unexplained symptoms plus an imaging study)

Most states allow 2–4 years from discovery. Because PowerPort complications can appear years after implantation, many claims are still timely even for devices implanted in 2015–2020. Do not self-assess as time-barred — consult an attorney.

Medicare, Medicaid, and ERISA Liens

Treatment for PowerPort complications — hospitalization, surgery, antibiotics, interventional radiology — is expensive. Medicare, Medicaid, and employer self-funded health plans (ERISA) all have subrogation rights to recover from any settlement.

Lien negotiation is a standard part of mass tort settlement practice. Experienced MDL attorneys have lien management departments or partner with lien resolution firms. Net-to-plaintiff calculation after lien payoff and attorney fees should be discussed with your attorney before accepting any settlement offer.

Mesothelioma Lawsuit Compensation — Understanding Medical Device and Toxic Exposure Settlement Structures

What to Do Now

Step 1: Identify whether your port is a Bard PowerPort product. Check your implant card, surgical records, or contact your implanting hospital’s medical records department.

Step 2: Document your complication. Gather all records related to the adverse event — hospitalization records, imaging reports, surgical reports.

Step 3: Note the timing. When was the port implanted? When was the complication identified? This determines whether you are within the SOL.

Step 4: Consult a medical device mass tort attorney. AAJ-member firms with MDL 3081 experience offer free initial consultations on contingency. The consultation costs you nothing and preserves your options.

Step 5: Do not delay. With bellwether trials ongoing in 2026, a settlement framework could emerge within the next 12–24 months. Attorneys typically need time to prepare claims before those deadlines are set.

Camp Lejeune Water Contamination Lawsuit — Federal Mass Tort Claim Process Comparison

The Damages Framework in PowerPort Cases

Understanding how damages are structured in a medical device mass tort helps patients evaluate whether a potential settlement is reasonable.

Economic Damages

Medical expenses — past and future:

• Hospitalization for infection treatment (ICU-level care for sepsis): $50,000–$200,000+
• Interventional radiology for fragment retrieval: $15,000–$40,000
• Open surgical retrieval (if IR fails): $50,000–$150,000
• Port removal and re-implantation surgery: $10,000–$30,000 each
• Anticoagulation treatment for thrombosis: variable by duration
• Future monitoring and follow-up imaging

Cancer treatment disruption: The most significant damages in cancer patient PowerPort cases often relate to treatment delay rather than the complication itself. If an infection caused a 2–8 week chemotherapy delay, experts can opine on whether that delay affected disease progression, staging changes, or survival probability. These damages require oncology expert analysis but can substantially increase the overall award.

Lost wages and earning capacity: For working-age patients, the inability to work during hospitalization and recovery is compensable. If the PowerPort complication caused a permanent functional impairment (e.g., cardiac injury from a catheter fragment), lost earning capacity can be projected over a working lifetime.

Non-Economic Damages

• Pain and suffering from the complication and procedures
• Emotional distress — particularly for cancer patients facing the dual burden of cancer treatment plus device failure
• Loss of consortium for spouses
• Loss of enjoyment of life

Punitive Damages

Available if plaintiffs can prove BD knew of the fracture risk and concealed it, acted with malice, or engaged in conduct rising above ordinary negligence. The FDA recall in 2020 and internal MDR documentation from before the recall are central to this argument.

Settlement Structure: What the IVC Filter Precedent Suggests

The Bard IVC Filter MDL (D. Arizona, same judge) resulted in multiple confidential settlement tranches over several years. The structure was roughly:

• Initial settlement tranche: resolved claims with the strongest evidence early
• Subsequent tranches: lower tiers for weaker claims
• Holdout litigation: small percentage of plaintiffs continued to trial

For PowerPort, a similar multi-tranche structure is plausible. Claims involving fracture with cardiac migration are at the top of the severity spectrum; claims involving uncomplicated infection without long-term sequelae may be in lower tiers.

The important lesson from IVC Filter: BD’s pattern is to settle, eventually — but to negotiate aggressively on tier values. Having strong medical documentation and experienced MDL counsel maximizes tier assignment.

The FDA MAUDE Database: How to Check Your Device

The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database contains Medical Device Reports (MDRs) submitted by manufacturers, distributors, and device users about medical device adverse events.

You can search MAUDE at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/ for “Bard PowerPort” or “PowerPort” to see reported adverse events including fractures, migrations, and infections. This database is publicly accessible and provides important context for understanding the scope of reported complications before and after the 2020 recall.

Your attorney will use MAUDE data in litigation to demonstrate that BD had notice of the failure pattern through submitted MDRs — a critical element of a concealment or failure-to-warn argument.

Comparing Catheter Port Types: Not All Ports Are Equal

Not every implanted port catheter is subject to MDL 3081. The litigation focuses specifically on Bard/BD products with the barium sulfate silicone catheter formulation.

Port Brand	Manufacturer	MDL 3081 Included?
PowerPort	Bard Access Systems (BD)	Yes
Eclipse Port	Bard Access Systems (BD)	Yes
X-Port	Bard Access Systems (BD)	Confirm model/year
Hickman/Broviac	BD/Bard	Separate device category
Mediport	AngioDynamics	No — different manufacturer
Port-A-Cath	Smiths Medical (ICU Medical)	No — different manufacturer

If your port is manufactured by AngioDynamics, ICU Medical, or another company, it is not part of MDL 3081. You may still have a product liability claim in state court if your device is linked to similar defects, but through a different legal pathway.

The implant card and surgical records will specify the manufacturer and model. If you cannot locate these, the implanting hospital’s medical records department can identify the device by its lot number from surgical records.

The Role of Treating Physicians in the Case

Your oncologist and the physician who implanted the port are important but distinct sources of evidence.

Implanting surgeon or interventional radiologist: Their records identify the device model, confirm proper implantation technique, and document any immediate complications. If the surgeon documented concerns about the device at removal — such as observing fracture characteristics or noting the catheter material appeared degraded — that contemporaneous clinical observation is powerful evidence.

Oncologist: Records of chemotherapy treatment delays or modifications due to the port complication are critical. If the oncologist notes that treatment was modified because of device-related infection or thrombosis, this directly documents the damages chain: device failure → treatment disruption → cancer outcome effect.

Infectious disease specialist (if infection): Detailed documentation of the organism, antibiotic regimen, hospitalization duration, and outcome. Blood culture results identifying a device-associated organism (e.g., Staphylococcus epidermidis, Staphylococcus aureus — common CRBSI pathogens) strengthen the infection causation argument.

Post-Settlement Life Care Planning

If your PowerPort complication caused permanent harm — cardiac injury, persistent pulmonary issues, or functional limitations from a complex retrieval surgery — a life care plan prepared by a certified life care planner (CLCP) projects your future medical needs and associated costs.

Life care plans in mass tort cases document:

• Future neurology, cardiology, or pulmonology follow-up visits
• Ongoing imaging requirements
• Rehabilitation needs
• Home health aide hours (if physical function affected)
• Adaptive equipment costs
• Inflation adjustments for all future costs

The life care plan becomes the basis for the economic damages claim for future expenses. In cases with significant permanent injury, this single document can add hundreds of thousands of dollars to the claimed damages.

Asbestos and IVC Filters: The Pattern of Repeat-Offender Medical Device Defendants

Bard/Becton Dickinson is not the first medical device company to face an MDL with fracture and migration as the core injury theory.

The historical pattern of medical device mass torts shows a consistent structure:

1. Device introduced with FDA clearance (not approval)
2. Post-market adverse event reports accumulate in MAUDE
3. Recall issued — often years after the problem is identifiable in MDR data
4. MDL consolidated — frequently in the same court that handled prior similar MDLs
5. Bellwether trials run — often resulting in plaintiff verdicts
6. Global settlement negotiated over 3–7 years

IVC filters (Bard, Cook Medical), metal-on-metal hip implants (DePuy, Stryker), and now PowerPort catheters follow this arc. Understanding the historical pattern helps manage realistic expectations about timeline.

Wrongful Death Lawsuit Settlement — When Device Failure Causes Fatal Outcomes

The Importance of Acting Before Settlement Deadlines

A common mistake in mass tort cases: waiting too long to retain counsel after a settlement is announced.

Once a claims administration process opens:

• Registration deadlines are typically 90–180 days
• Documentation submission deadlines follow
• Appeals of tier assignments have additional deadlines

If you miss the registration deadline, you are out. Courts enforce these deadlines strictly because mass tort administration requires finality.

The gap between “first bellwether verdict” and “claims period opening” can be short — sometimes under 12 months. With the Cook bellwether trial ongoing now, that clock is ticking for PowerPort claimants.

Retaining counsel now — before any settlement is announced — means your attorney is prepared to register your claim the moment the process opens. Waiting until the settlement is announced often means rushing documentation preparation under deadline pressure.

Asbestos Exposure Lawsuit — The Foundational Mass Tort That Established MDL Practice

Frequently Asked Questions from PowerPort Patients

Q: My PowerPort was implanted in 2016 and never caused any problems. Should I be concerned?

Not every PowerPort fails. If you have not experienced a fracture, significant infection, or thrombosis, you do not have a current claim. The litigation involves patients who experienced actual documented injuries. However, if you develop complications in the future, your medical records from implantation onward will be critical. Keep your implant card.

Q: The hospital that implanted my port closed down. How do I get my records?

Medical records must be retained for a minimum number of years under state law (typically 7–10 years for adults). Contact your state health department or a medical records retrieval service if the hospital closed. Records may have been transferred to another provider system. Your attorney can assist with this process.

Q: I had a PowerPort infection but recovered fully and have no lasting effects. Is my case worth pursuing?

Cases involving minor, fully resolved infections are typically lower-tier claims — if they qualify at all. The litigation focuses most heavily on cases where the complication caused significant harm: prolonged hospitalization, cancer treatment delay, permanent injury, or significant medical costs. A consultation with a mass tort attorney can help you assess whether your specific circumstances meet a viable threshold.

Q: My PowerPort was removed because it “stopped working” but no one mentioned fracture or migration. Should I investigate further?

Yes. “Stopped working” could indicate a catheter occlusion (clot) — compensable as thrombosis. It could also indicate early-stage fracture or migration not yet symptomatic. Request all imaging performed around the time of removal and ask the removing physician for specifics on why removal was necessary. Your attorney can evaluate the records.

Q: I am currently undergoing chemotherapy. Can I pursue a claim right now?

Yes. Being in active cancer treatment does not disqualify you. However, the logistics should be manageable — most communication with your attorney can be done remotely, and you are not required to appear in court during the initial claim process. Your current health status and treatment are actually relevant to damages calculation.

Mesothelioma Lawsuit Compensation — Cancer Patients Navigating Mass Tort Claims